This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

2 Health Care Stocks Rising on Big Volume

Stocks in this article: TROV ADUS

TrovaGene

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

TrovaGene ( TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.

Friday's Volume: 712,000
Three-Month Average Volume: 183,106
Volume % Change: 294%

>>4 Biotech Stocks Under $10 to Trade for Breakouts

From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.

Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs